Cardiac amyloidosis MRI: Difference between revisions
(→MRI) |
(/* ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance{{cite journal| author=American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Fi...) |
||
Line 11: | Line 11: | ||
CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including | CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including | ||
*Evaluation of [[dilated cardiomyopathy]] in the setting of normal coronary arteries | *Evaluation of [[dilated cardiomyopathy]] in the setting of normal coronary arteries | ||
*Patients with positive cardiac enzymes without obstructive atherosclerosis on angiography | *Patients with positive cardiac enzymes without obstructive [[atherosclerosis]] on [[angiography]] | ||
*Patients suspected of amyloidosis or other infiltrative diseases | *Patients suspected of [[amyloidosis]] or other infiltrative diseases | ||
*Hypertrophic cardiomyopathy | *[[Hypertrophic cardiomyopathy]] | ||
*Arrhythmogenic right ventricular dysplasia | *[[Arrhythmogenic right ventricular dysplasia]] | ||
*Syncope or ventricular arrhythmia | *[[Syncope]] or [[ventricular arrhythmia]] | ||
}} | }} | ||
Revision as of 18:41, 4 May 2013
Cardiac amyloidosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cardiac amyloidosis MRI On the Web |
American Roentgen Ray Society Images of Cardiac amyloidosis MRI |
Risk calculators and risk factors for Cardiac amyloidosis MRI |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2]; Aarti Narayan, M.B.B.S [3]
Overview
Amyloidosis is an infiltrative disease resulting in deposition of amyloid in the extracellular spaces of the tissues. Amyloid infiltration of the heart leads to expansion of these extracellular spaces resulting in retainment of gadolinium dye during cardiac magnetic resonance imaging. This retainment of gadolinium leads to signal enhancement in the late washout phase during delayed enhanced cardiac imaging.
MRI
ACC/AHA Guidelines- ACCF/ACR/AHA/NASCI/SCMR 2010 Expert Consensus Document on Cardiovascular Magnetic Resonance[1] (DO NOT EDIT)
“ |
CMR may be used for assessment of patients with LV dysfunction or hypertrophy or suspected forms of cardiac injury not related to ischemic heart disease. When the diagnosis is unclear, CMR may be considered to identify the etiology of cardiac dysfunction in patients presenting with heart failure, including
|
” |
References
- ↑ American College of Cardiology Foundation Task Force on Expert Consensus Documents. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA; et al. (2010). "ACCF/ACR/AHA/NASCI/SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents". Circulation. 121 (22): 2462–508. doi:10.1161/CIR.0b013e3181d44a8f. PMC 3034132. PMID 20479157.